BridgeBio Pharma, Inc. Income (Loss) from Equity Method Investments
BridgeBio Pharma, Inc. (BBIO) reported Income (Loss) from Equity Method Investments of -$6.43 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2026-08-10
- BridgeBio Pharma, Inc. income (loss) from equity method investments for the quarter ending 2026-06-30 was -$6.43M.
- BridgeBio Pharma, Inc. income (loss) from equity method investments for the quarter ending 2026-03-31 was -$18.28M.
- BridgeBio Pharma, Inc. income (loss) from equity method investments for the quarter ending 2025-12-31 was -$21.03M.
- BridgeBio Pharma, Inc. income (loss) from equity method investments for the quarter ending 2025-09-30 was -$15.83M.
- BridgeBio Pharma, Inc. income (loss) from equity method investments for fiscal 2025 was -$72.61M.
- BridgeBio Pharma, Inc. income (loss) from equity method investments for fiscal 2024 was -$31.18M.
- BridgeBio Pharma, Inc. income (loss) from equity method investments for fiscal 2023 was $0.00.
- BridgeBio Pharma, Inc. income (loss) from equity method investments for fiscal 2022 was $0.00.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$6.43M 10-Q · filed 2026-08-10 | -$24.72M 10-Q · filed 2026-08-10 | -$45.75M derived: sum of 3 quarters · filed 2026-08-10 | -$61.58M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$18.28M 10-Q · filed 2026-05-07 | -$39.31M derived: sum of 2 quarters · filed 2026-05-07 | -$55.15M derived: sum of 3 quarters · filed 2026-05-07 | -$75.33M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$21.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$36.86M derived: sum of 2 quarters · filed 2026-02-24 | -$57.05M derived: sum of 3 quarters · filed 2026-08-10 | -$72.61M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$15.83M 10-Q · filed 2025-10-29 | -$36.02M derived: sum of 2 quarters · filed 2026-08-10 | -$51.58M 10-Q · filed 2025-10-29 | -$68.27M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$20.19M 10-Q · filed 2026-08-10 | -$35.74M 10-Q · filed 2026-08-10 | -$52.44M derived: sum of 3 quarters · filed 2026-08-10 | -$59.00M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$15.56M 10-Q · filed 2026-05-07 | -$32.25M derived: sum of 2 quarters · filed 2026-05-07 | -$38.81M derived: sum of 3 quarters · filed 2026-05-07 | -$46.74M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$16.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$23.26M derived: sum of 2 quarters · filed 2026-02-24 | -$31.18M derived: sum of 3 quarters · filed 2026-02-24 | -$31.18M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$6.56M 10-Q · filed 2025-10-29 | -$14.49M derived: sum of 2 quarters · filed 2025-10-29 | -$14.49M 10-Q · filed 2025-10-29 | -$14.49M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$7.92M 10-Q · filed 2025-08-05 | -$7.92M 10-Q · filed 2025-08-05 | -$7.92M derived: sum of 3 quarters · filed 2026-02-24 | -$7.92M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $0.00 10-Q · filed 2025-04-29 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 10-K · filed 2026-02-24 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-01 | $0.00 10-Q · filed 2024-08-01 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-02-20 | |||
| 2019-12-31 | -$4.72M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$11.31M derived: sum of 2 quarters · filed 2022-02-25 | -$16.27M derived: sum of 3 quarters · filed 2022-02-25 | -$20.87M 10-K · filed 2022-02-25 |
| 2019-09-30 | -$6.59M 10-Q · filed 2020-11-05 | -$11.54M derived: sum of 2 quarters · filed 2020-11-05 | -$16.14M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | -$4.96M 10-Q · filed 2020-08-11 | -$9.55M 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | -$4.60M 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | -$275.00K 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |